A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma.
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms SPIRIT
- Sponsors Novartis
- 05 May 2017 Planned End Date changed from 1 Nov 2021 to 15 Jul 2022.
- 05 May 2017 Planned primary completion date changed from 1 Nov 2021 to 15 Jul 2022.
- 05 May 2017 Status changed from not yet recruiting to recruiting.